LINC00863: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC00863

NCBI ID: G439994

LINC00863

Other Name(s): long intergenic non-protein coding RNA 863 | Long intergenic non-protein coding RNA 863, transcript variant 2

LINC00863: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC00863 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature that consists of 1,262 exons, 11 introns, and 11 exons, which are dispersed across different genomes. LINC00863 has been shown to play a crucial role in various biological processes, including cell growth, development, and disease.

Drug Target Potential

LINC00863 has been identified as a potential drug target due to its unique structure and various functions. One of its exons has been shown to encode a protein that can interact with multiple drug targets, including those involved in cell signaling pathways, cell adhesion, and inflammation . Additionally, LINC00863 has been shown to play a role in the regulation of cellular processes that are associated with various diseases, such as cancer, neurodegenerative diseases, and autoimmune diseases.

Biomarker Potential

LINC00863 has also been identified as a potential biomarker for various diseases. Its unique structure and various functions make it an attractive candidate for diagnostic and therapeutic applications. For example, LINC00863 has been shown to be expressed in various tissues and fluids, including blood, urine , and tissue samples from cancer patients. Additionally, its expression has been shown to be associated with various diseases, such as neurodegenerative diseases and autoimmune diseases.

Expression and Regulation

LINC00863 has been shown to be expressed in various tissues and organs, including the brain, pancreas, and heart. Its expression has been shown to be regulated by various factors, including DNA binding, RNA binding, and post-transcriptional regulation.

Expression and regulation

LINC00863 has been shown to be involved in various signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. Its expression has been shown to be regulated by various transcription factors, including GTF1, PDGF- 1, and NF-kappa-B1.

Function and Interaction

LINC00863 has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. expression has been shown to interact with various proteins, including drug targets involved in cell signaling pathways.

Conclusion

In conclusion, LINC00863 is a long intergenic non-protein-coding RNA that has unique features and functions. Its expression and regulation in various tissues and organs make it a potential drug target and biomarker. Further research is needed to fully understand its role in various biological processes and its potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 863

The "LINC00863 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00863 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets